Drug Overview

Erdafitinib is a groundbreaking Targeted Therapy and “Smart Drug” used to treat advanced bladder cancer. Unlike traditional chemotherapy that affects many different types of cells, erdafitinib is designed to find and block specific proteins that help cancer cells grow and spread.

By acting like a “precision filter,” this medication helps patients whose cancer has a specific genetic change. It allows for a more personalized approach to cancer care, focusing on the unique DNA of the tumor itself.

Generic Name: Erdafitinib
US Brand Names: Balversa®
Drug Class: Kinase Inhibitor; Fibroblast Growth Factor Receptor (FGFR) Inhibitor
Route of Administration: Oral (Tablet taken by mouth)
FDA Approval Status: FDA-Approved for specific types of urothelial carcinoma (cancer of the bladder or urinary tract).

What Is It and How Does It Work? (Mechanism of Action)

To understand erdafitinib, think of cancer cells as having “stuck switches.” In many bladder cancers, a protein called the Fibroblast Growth Factor Receptor (FGFR) acts like a master switch on the surface of the cell. In healthy cells, this switch turns on and off to control growth. However, in some cancers, a genetic mutation causes this switch to stay “ON” all the time, sending constant signals for the cell to multiply.

At the molecular level, erdafitinib works through a precise process:

Binding: Erdafitinib travels through the bloodstream and enters the cancer cells. It specifically seeks out the tyrosine kinase domain of FGFR1, FGFR2, FGFR3, and FGFR4.
Blocking the Signal: The drug binds to these receptors, acting like a “plug” in an electrical socket. This prevents the receptors from sending growth signals.
Interrupting Pathways: By blocking these receptors, erdafitinib shuts down several signaling “highways” inside the cell, such as the MAPK and PI3K/Akt pathways.
Cell Death: Without these growth signals, the cancer cell stops dividing and eventually dies.

FDA-Approved Clinical Indications

Erdafitinib is used for patients with “urothelial carcinoma,” which is the most common form of bladder cancer.

Oncological Uses:

Advanced Bladder Cancer: For adult patients with locally advanced or metastatic urothelial carcinoma that has spread.
Genetic Requirement: The cancer must have specific genetic “mistakes” (FGFR3 or FGFR2 alterations) as determined by an FDA-approved test.
Prior Treatment: It is used for patients whose cancer has progressed during or after at least one line of prior systemic therapy (such as chemotherapy or immunotherapy).

Non-oncological Uses:

There are currently no approved non-oncological uses for this medication.

Dosage and Administration Protocols

Erdafitinib is a daily pill. A unique part of this treatment is the “dose titration,” where the doctor may increase the dose based on your blood phosphate levels.

Parameter	Standard Protocol
Initial Starting Dose	8 mg taken once daily
Dose Titration	May increase to 9 mg daily (if blood phosphate is low between days 14–21)
Administration	Take at the same time each day, with or without food
Form	Oral Tablet

Dose Adjustments:

Renal (Kidney) Insufficiency: No adjustment is usually needed for mild to moderate kidney issues.
Hepatic (Liver) Insufficiency: Use with caution in patients with moderate to severe liver issues; doses may be reduced or paused if liver enzymes rise.
Eye Problems: If vision changes occur, the dose may be stopped or lowered.

Clinical Efficacy and Research Results

Clinical trials conducted between 2020 and 2025 (such as the THOR trial) have shown that erdafitinib is more effective than chemotherapy for patients with these specific genetic changes.

Overall Survival (OS): In the Phase 3 THOR study (updated in 2024), patients taking erdafitinib lived significantly longer than those on chemotherapy. The median overall survival was 12.1 months for erdafitinib compared to 7.8 months for chemotherapy.
Risk Reduction: Research showed a 36% reduction in the risk of death compared to traditional chemotherapy in patients with FGFR alterations.
Response Rate: Approximately 35% to 40% of patients saw their tumors shrink significantly (Objective Response Rate) during early trials.

Safety Profile and Side Effects

Because erdafitinib blocks a growth factor that is also used by healthy tissues (like the eyes and skin), it has specific side effects.

Black Box Warning:

There is no official Black Box Warning, but there is a Major Warning regarding Eye Disorders, specifically a condition called Central Serous Retinopathy (CSR).

Common Side Effects (>10%):

Hyperphosphatemia: High phosphate levels in the blood (affects over 70% of patients).
Mouth Sores: Redness or pain in the mouth (stomatitis).
Nail Changes: Nails becoming brittle, painful, or separating from the bed.
Dryness: Dry mouth, dry skin, and dry eyes.
Fatigue: Feeling unusually tired.

Serious Adverse Events:

Eye Damage: Fluid buildup under the retina (CSR) causing blurred vision or “blind spots.”
Severe Skin Reactions: Peeling or painful rashes.

Management Strategies: High phosphate is managed with a low-phosphate diet or special “phosphate-binder” medications. Mouth sores are managed with salt-water rinses and avoiding spicy foods.

Research Areas

In the 2025–2026 research landscape, erdafitinib is being studied in combination with Immunotherapy drugs (like pembrolizumab). Scientists are also looking at its “tumor-agnostic” potential—meaning it might work for other types of cancer (like lung or bile duct cancer) as long as those tumors have the same FGFR genetic mutations. While not a stem cell therapy itself, it is being researched for how it affects the “microenvironment” where cancer stem cells hide.

Patient Management and Practical Recommendations

Pre-treatment Tests to be Performed:

Genetic Testing: Confirm the tumor has FGFR3 or FGFR2 alterations.
Eye Exam: A baseline check by an ophthalmologist (specifically a retinal exam).
Blood Phosphate: To know your starting level.

Precautions During Treatment:

Eye Monitoring: You must have your eyes checked every month during the first few months.
Skin Care: Use thick, fragrance-free moisturizers and sunscreen.

“Do’s and Don’ts” List:

DO report any blurred vision or “flashes of light” to your doctor immediately.
DO follow a low-phosphate diet (avoiding too many dairy products, nuts, and dark sodas).
DON’T take extra doses if you miss one; just take the next dose at the regular time.
DON’T stop the medication without talking to your oncologist, even if you have nail or skin issues.

Legal Disclaimer

The information in this guide is for educational purposes only and does not replace professional medical advice. Erdafitinib (Balversa) is a prescription medicine that must be managed by an oncology specialist. Side effects and results can vary between patients. Always consult your healthcare provider regarding your specific treatment plan. If you experience a medical emergency, call 911 or your local emergency services immediately.